A Phase 4 interventional study of Tobramycin inhalation solution and 0.9% Sodium Chloride Placebo in Pneumonia, Ventilator-Associated, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Pneumonia, Ventilator-Associated with a site in China — 10 open to participants now, 11 under way, none of them phase 3. Pneumonia, Ventilator-Associated · China.
Among the 26 studies in Pneumonia, Ventilator-Associated with a site in China, this one is the 2nd largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 4, reaches primary completion later than 9 of the 10 other live ones, and was the 26th registered.
420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.
Browse Pneumonia, Ventilator-Associated studies →10 of the 26 studies in Pneumonia, Ventilator-Associated with a site in China are open now. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Sir Run Run Shaw Hospital · Sites in China
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18–90
Qilu Hospital of Shandong University · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 2
First in 2009; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 574 is above the median of 115 across 276 interventional studies indexed under Pneumonia, Ventilator-Associated.
Median enrollment 174 across the 17 interventional studies, 200 across the 9 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 26 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 108 studies on the registry; 73 are open to participants now.
Second Affiliated Hospital, Zhejiang University, School of Medicine has 1 study filed under Pneumonia, Ventilator-Associated — fewer than ten, so there is no comparison to draw.
3 of the studies in Pneumonia, Ventilator-Associated with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06819462Southeast University, ChinaInhaled Colistin to Prevent Ventilator-Associated Pneumonia in Patients With Acute Brain Injury | 2026-12-31 |
| NCT07512596Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria | 2027-07 |
| NCT07268560Sir Run Run Shaw HospitalReal-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies in Pneumonia, Ventilator-Associated with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The TOP-MDRVAP trial will test whether inhaled tobramycin can safely prevent pneumonia caused by multidrug-resistant bacteria in adults who need a breathing machine. Tobramycin is an antibiotic. Multidrug-resistant bacteria are bacteria that resist treatment with several types of antibiotics. Pneumonia that develops in patients receiving breathing support through a breathing tube is called ventilator-associated pneumonia (VAP). This study will evaluate tobramycin as a preventive treatment, rather than as treatment for existing VAP.
The study plans to enroll 574 adults aged 18 years or older in intensive care units (ICUs) at several hospitals. Participants must have received breathing support through a tube for 72 to 96 hours and be expected to need this support for at least another 72 hours. They must have at least one risk factor for infection with multidrug-resistant bacteria and must not have suspected or confirmed VAP when entering the study.
Participants will be assigned by chance to one of two groups, with an equal chance of entering either group. One group will receive tobramycin inhalation solution, 300 mg in 5 mL, twice daily for 3 consecutive days. The other group will receive 5 mL of 0.9% saline, a saltwater solution containing no antibiotic, on the same schedule. A nebulizer will turn the solution into a fine mist delivered through the breathing tube.
Both groups will receive standard measures to prevent VAP. Participants, their representatives, the healthcare professionals providing their direct care, and the researchers assessing outcomes will not know which study treatment each participant receives.
The main question is whether fewer participants develop VAP caused by multidrug-resistant bacteria within 28 days after assignment to a study group. Researchers will also compare the occurrence of VAP from any cause, antibiotic use, time receiving breathing support, time spent in the ICU and hospital, and deaths within 28 and 90 days.
Participants will be monitored for possible side effects, including kidney problems, narrowing of the airways, and complications involving the breathing tube or equipment. Samples will be tested for bacteria and antibiotic resistance. Follow-up will continue for up to 90 days after assignment, using hospital records or telephone contact to assess survival and recovery milestones, including discharge and the end of breathing support.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least one of the following risk factors for multidrug-resistant (MDR) bacterial infection:
3.1 Exposure to systemic antibiotics for ≥24 hours within the 30 days before enrollment.
3.2 Current hospitalization for at least 120 hours before randomization. 3.3 Septic shock requiring vasoactive medication to maintain a mean arterial pressure ≥65 mmHg, with a blood lactate level >2 mmol/L.
3.4 Moderate-to-severe acute respiratory distress syndrome (ARDS), according to the Berlin definition, with a PaO2/FiO2 ratio ≤200 mmHg and positive end-expiratory pressure (PEEP) ≥5 cm H2O.
3.5 Current renal replacement therapy, including continuous renal replacement therapy or intermittent hemodialysis.
3.6 A history of MDR bacterial colonization or infection within the previous 12 months, documented by clinical culture.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive tobramycin inhalation solution, 300 mg in 5 mL per dose, administered through the endotracheal tube using a vibrating mesh nebulizer twice daily for 3 consecutive days (6 planned doses). The intervention is administered to prevent multidrug-resistant ventilator-associated pneumonia (MDR-VAP). Participants also receive standard ventilator-associated pneumonia (VAP) prevention measures.
Drug: Tobramycin inhalation solution
Participants receive 5 mL of 0.9% sodium chloride solution (normal saline) as a placebo, administered through the endotracheal tube using a vibrating mesh nebulizer twice daily for 3 consecutive days (6 planned doses). Participants also receive standard ventilator-associated pneumonia (VAP) prevention measures.
Drug: 0.9% Sodium Chloride Placebo
Tobramycin inhalation solution (300 mg/5 mL) is administered at a dose of 300 mg (5 mL) twice daily for 3 consecutive days, for a total of 6 planned doses. The ready-to-use solution is administered without additional dilution through the endotracheal tube using a vibrating mesh nebulizer connected to the ventilator circuit. Each nebulization continues until the nebulizer reservoir is empty. The intervention is administered to prevent multidrug-resistant ventilator-associated pneumonia (MDR-VAP), in addition to standard VAP prevention measures.
A 5 mL dose of 0.9% sodium chloride solution (normal saline) is administered as a placebo twice daily for 3 consecutive days, for a total of 6 planned doses. The solution is delivered through the endotracheal tube using the same type of vibrating mesh nebulizer, administration schedule, and nebulization procedure as the tobramycin intervention. Each nebulization continues until the nebulizer reservoir is empty. Participants also receive standard VAP prevention measures.
28-Day Cumulative Incidence of Multidrug-Resistant Ventilator-Associated Pneumonia
Percentage of randomized participants with a first episode of multidrug-resistant ventilator-associated pneumonia (MDR-VAP), adjudicated by an independent blinded endpoint adjudication committee. VAP develops after 48 hours of mechanical ventilation, including within 48 hours after weaning or extubation. Diagnosis requires new or progressive infiltrates, consolidation, or ground-glass opacities on chest X-ray or CT plus at least two of: temperature \>38°C, purulent airway secretions, and white blood cell count \>10 x 10\^9/L or \<4 x 10\^9/L. MDR-VAP additionally requires a positive quantitative lower respiratory tract culture (tracheal aspirate ≥10\^5 CFU/mL; bronchoalveolar lavage ≥10\^4 CFU/mL; protected specimen brush ≥10\^3 CFU/mL) with a causative bacterium resistant to at least three antimicrobial classes.
Time frame: From randomization through Day 28.
Incidence Density of Multidrug-Resistant Ventilator-Associated Pneumonia
Number of first episodes of multidrug-resistant ventilator-associated pneumonia per 1,000 invasive mechanical ventilation days accumulated during the assessment period.
Time frame: From randomization through Day 28.
28-Day Incidence of Ventilator-Associated Pneumonia From Any Cause
28-Day Incidence of Ventilator-Associated Pneumonia From Any Cause
Time frame: From randomization through Day 28.
Systemic Antibiotic Use Expressed as Antibiotic-Days
Cumulative systemic antibiotic use during the assessment period, expressed as antibiotic-days.
Time frame: From randomization through Day 28.
Days of Exposure to Systemic Antibiotics
Number of days on which a participant receives at least one systemic antibiotic during the assessment period. Each day with systemic antibiotic exposure is counted once, regardless of the number of antibiotics administered.
Time frame: From randomization through Day 28.
Duration of Mechanical Ventilation
Total duration of invasive and noninvasive mechanical ventilation, measured in days, during the assessment period.
Time frame: From randomization through Day 28.
Intensive Care Unit Length of Stay
Duration of intensive care unit stay, measured in days from randomization to ICU discharge, with follow-up through Day 90.
Time frame: From randomization to ICU discharge, assessed up to Day 90.
Hospital Length of Stay
Duration of hospital stay, measured in days from randomization to hospital discharge, with follow-up through Day 90.
Time frame: From randomization to hospital discharge, assessed up to Day 90.
28-Day All-Cause Mortality
Percentage of participants who die from any cause within 28 days after randomization.
Time frame: From randomization through Day 28.
90-Day All-Cause Mortality
Percentage of participants who die from any cause within 90 days after randomization. Survival status is obtained from hospital records or telephone follow-up.
Time frame: From randomization through Day 90.
Incidence of Ventilator-Associated Pneumonia Caused by Tobramycin-Susceptible Gram-Negative Bacteria
Percentage of participants who develop ventilator-associated pneumonia caused by gram-negative bacteria that are susceptible to tobramycin on in vitro antimicrobial susceptibility testing.
Time frame: From randomization through Day 28.
Incidence of Ventilator-Associated Events
Percentage of participants who develop a ventilator-associated event, assessed using the protocol-specified 2023 Centers for Disease Control and Prevention/National Healthcare Safety Network definitions. Assessments include ventilator-associated conditions, infection-related ventilator-associated complications, and possible ventilator-associated pneumonia.
Time frame: From randomization through Day 28.
Incidence of New-Onset Acute Kidney Injury
Percentage of participants without acute kidney injury at baseline who develop Kidney Disease: Improving Global Outcomes (KDIGO) stage 1 or higher acute kidney injury during the assessment period.
Time frame: From randomization through Day 28.
Daily Trajectory of the Clinical Pulmonary Infection Score
Daily Clinical Pulmonary Infection Score (CPIS) values and their longitudinal changes during the assessment period, calculated using available clinical data.
Time frame: Assessed daily from randomization until extubation or Day 28, whichever occurs first.
Time to First Successful Spontaneous Breathing Trial
Time, measured in days, from randomization to the first successful spontaneous breathing trial (SBT) during the assessment period.
Time frame: From randomization through Day 28.
Detection Rate of Tobramycin-Resistant Bacteria
Rate of isolation of tobramycin-resistant bacteria from respiratory specimens or blood cultures during the assessment period.
Time frame: From randomization through Day 28.
Composite Incidence of Serious Nebulization-Related Adverse Effects
Percentage of participants experiencing at least one serious adverse effect related to nebulization, including increased expiratory filter resistance, bronchospasm, or endotracheal tube obstruction.
Time frame: From randomization through Day 28.
Longitudinal Changes in Respiratory Microbiome Alpha Diversity
Longitudinal changes in respiratory microbiome alpha diversity, assessed by 16S ribosomal RNA amplicon sequencing in participants enrolled in the microbiome substudy.
Time frame: Protocol-specified Days 1, 4, 7, and 14, with additional sampling at VAP onset.
Longitudinal Changes in Respiratory Microbiome Beta Diversity
Longitudinal changes in respiratory microbiome beta diversity, assessed by 16S ribosomal RNA amplicon sequencing in participants enrolled in the microbiome substudy.
Time frame: Protocol-specified Days 1, 4, 7, and 14, with additional sampling at VAP onset.
Longitudinal Changes in Antibiotic Resistance Gene Abundance
Longitudinal changes in antibiotic resistance gene abundance in respiratory samples, assessed by metagenomic next-generation sequencing.
Time frame: Protocol-specified Days 1, 4, 7, and 14, with additional sampling at VAP onset.
Longitudinal Changes in Antibiotic Resistance Gene Diversity
Longitudinal changes in antibiotic resistance gene diversity in respiratory samples, assessed by metagenomic next-generation sequencing.
Time frame: Protocol-specified Days 1, 4, 7, and 14, with additional sampling at VAP onset.
Tobramycin Concentration-Time Profile in Epithelial Lining Fluid
Tobramycin concentrations in epithelial lining fluid over time in participants enrolled in the pharmacokinetic substudy.
Time frame: During the 3-day study treatment period.
Plasma Tobramycin Concentration-Time Profile
Plasma tobramycin concentrations over time in participants enrolled in the pharmacokinetic substudy.
Time frame: During the 3-day study treatment period.
Plan to share: Yes — De-identified individual participant data underlying the results reported in the primary publication of the TOP-MDRVAP trial will be shared, together with a data dictionary. The dataset will include baseline characteristics, treatment allocation, and data supporting the reported efficacy and safety outcomes. Direct identifiers and the participant identification linkage file will not be shared. Data will be made available through controlled access for approved research proposals, subject to participant consent, institutional and ethics requirements, and applicable data-protection regulations.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data and supporting documents will be available beginning 6 months after publication of the primary trial results and ending 5 years after that publication.
Access criteria: Access will be available to qualified researchers who submit a methodologically sound proposal for secondary analyses or individual participant data meta-analyses. Requests should be submitted to the principal investigator through the study contact listed in the trial registry. The principal investigator and the study Executive Committee will review the scientific merit, feasibility, and data-protection safeguards of each request. Approved applicants must sign a data use agreement limiting use to the approved research, prohibiting participant re-identification and unauthorized onward sharing, and requiring secure data storage. Data will be provided by secure electronic transfer after any required institutional, ethics, or regulatory approvals have been obtained.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tobramycin
Pneumonia, Ventilator-Associated →
Second Affiliated Hospital, Zhejiang University, School of Medicine →